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Summary.-The steroids prednisolone and progesterone significantly altered the
therapeutic indices of the alkylating agents, nitrogen mustard, melphalan, cyclo-
phosphamide, phenyl acetic mustard and chlorambucil. For nitrogen mustard,
chlorambucil and phenyl acetic mustard, prednisolone reduced host toxicity in the
rat and enhanced the antitumour effectiveness against alkylating-agent-resistant
strains of the Yoshida sarcoma and Walker carcinosarcoma. Progesterone also
increased the therapeutic index of chlorambucil in the rat by decreasing its systemic
toxicity.
Two other alkylating agents, melphalan and cyclophosphamide, exhibited lower
therapeutic indices in combination with prednisolone against alkylating-agent-
sensitive tumours. This was due to the greater host toxicity of the combination than
of the alkylating agent alone. In alkylating-agent-resistant tumours, however, a
significant increase in growth delay was achieved if prednisolone was combined
with the alkylating agent.
IN THE TREATMENT of malignant
diseases, alkylating agents, intercalating
antibiotics, antimetabolites and Vinca
alkaloids are often used in combination
(Ziegler et al., 1972; Tucker et al., 1968;
Bodey et al., 1973). However, the refrac-
tive nature of many tumours, and the
heterogeneity of their drug sensitivity,
has necessitated the use of increasingly
high doses of drugs to achieve a tumour
response. The margin oftolerance between
tumour response and the systemic toxicity
to the host has therefore narrowed. The
use of pretreatment with cyclophospha-
mide (Hedley et al., 1978) and marrow
autotransplantation (McElwain et al.,
1979) have been used successfully in
combination with high-dose melphalan,
but there is a clear need for other ap-
proaches to widen the therapeutic gap.
We have previously shown that pred-
nisolone is able to improve the thera-
peutic index of chlorambucil in an experi-
* To whom all correspondence should be addressedl.
mental tumour system (Harrap et al.,
1977). Host toxicity was reduced
and tumour-cell kill maintained. Further,
a tumour with acquired resistance which
was refractory to chlorambucil alone
responded to the combined treatment.
Prednisolone is frequently included in
clinical treatment schedules especially for
tumours of the lympho-proliferative sys-
tem, where tumoricidal effects could be
expected from the corticosteroid alone
(Scavino et al., 1976; Land et al., 1976;
Whitecar et al., 1972). In our experimental
system, however, the tumour did not
respond to prednisolone alone (Harrap
et al., 1977). In view of the extensive
clinical use of alkylating drugs we thought
it important to determine whether the
enhanced therapeutic index in a non-
steroid-responsive tissue could be extended
to other alkylating agent/steroid combina-
tions or whether it was a property
peculiar to chlorambucil.R. SHEPHERD AND K. R. HARRAP
We now present data on the toxicity
and antitumour activity of a number of
alkylating agent/steroid combinations in
2 different experimental tumour systems
in vivo. An abstract of preliminary
results of this study has already been
published (Wilkinson & Harrap, 1978).
MATERIALS AND METHODS
Chlorambucil (4,'-(2-dichloroethyl)-amino)-
phenyl butyrate, CHL) was a generous
gift from the Wellcome Foundation, Becken-
ham, Kent. Melphalan (L,p-(2-dichloro-
ethyl)-amino)-phenyl alanine, MEL) and
phenyl acetic mustard, 4,p-(2-(dichloro-
ethyl)-amino)-phenyl acetate, PAM) were
synthesized in the Chester Beatty Research
Institute (London). Nitrogen mustard
(methyl-bis-chloroethyl amine, HN2) was
purchased from The Boots Co. Ltd
(Nottingham) and cyclophosphamide (2-(bis
(2-chloroethyl) -amino) -2H -1,3,2-oxazaphos-
phorinane 2-oxide, CY) from WB Pharma-
ceuticals (Bracknell, Berks). Prednisolone
(PRED) was purchased from Sigma
(Kingston-upon-Thames) and progesterone
(PROG) was obtained from Organon
Laboratories Ltd (Morden, Surrey).
All other chemicals were purchased from
either Hopkin and Williams (Chadwell Heath,
Essex) or BDH (Poole, Dorset), AnalaR
grades being used where available.
Tumour lines.-Wistar rats were used for
all studies on the Yoshida sarcoma and
Walker 256 carcinosarcoma. Two lines of
Yoshida sarcoma ascites, one sensitive to
alkylating agents and one with a 50-fold
acquired resistance (Harrap & Furness,
1973), were routinely passaged weekly.
Tumour cells were removed from the peri-
toneal cavity using a sterile 0-9% NaCl
solution, and an aliquot counted with a
Coulter electronic particle counter (Model
ZF). Aliquots of tumour cells (106, 2 x 106 or
107) were injected i.p. into recipient rats
(Harrap & Hill, 1969).
The resistant strain of the Walker carcino-
sarcoma was developed in vitro by repeated
CHL treatments (Tisdale & Phillips, 1976)
and both sensitive and resistant Walker
tumours were passaged as ascites tumours as
described for the Yoshida tumour. The
ADJ/PC6A plasmacytoma was maintained
as a solid tumour passaged s.c. every 21 days
by trochar as a 1mm3 implant fragment
(Connors et al., 1972).
Antitumour studies and drug treatments.-
For antitumour studies on the Yoshida
sarcoma the cells in the peritoneal cavity
were counted each day for 3 days after drug
treatments, as previously described (Harrap
& Hill, 1969). Drugs were administered s.c.
in the back of the neck 3 days after tumour
implant. Studies on the Walker tumour
were performed in two ways. The tumour
was injected i.p. as an ascites and cells
counted for 3 days, as for the Yoshida
tumour. In these cases rats received s.c.
drug treatments in the back of the neck. Or
the Walker tumour cells were injected i.m. in
one hind leg, where a solid tumour developed.
The untreated tumour grew to a weight of
9-10 g in 8 days. The weight of tumour in
the drug-treated animals was compared with
that of the untreated controls 8 days after
tumour implant. Rats bearing the solid
tumours were treated i.p. or s.c. one day
after tumour implant (Rosenoer et al., 1966).
The ADJ/PC6A tumour was implanted s.c.
in the flank, and drug treatments were given
i.p. 24 days later. The weights of tumour in
drug-treated and control mice were com-
pared 10 days after drug treatment, when the
untreated tumours weighed 8-9 g (Connors
et al., 1972). CHL and PRED were dissolved
in dimethyl sulphoxide (DMSO), MEL in
ethanolic HCl-phosphate, propylene glycol
(Harrap & Hill, 1969) and CY and PROG in
0.9% NaCl. The steroids were always given
in equimolar doses to those of the alkylating
agent, because this combination had proved
effective in the form of the steroid ester
prednimustine, which is inactive until hydro-
lysed to its component molecules (Wilkinson
et al., 1978; Harrap et al., 1977).
RESULTS
In the rat, the systemic toxicity of
either HN2 (Fig. 1) or PAM (Table I) was
reduced if the alkylating agent was
administered in combination with PRED.
Fig. 1 details the systemic toxicity
following a dose of 1 mg/kg of HN2, but
no deaths occurred if this was accom-
panied by an equimolar (3 mg/kg) dose
of PRED. The steroid was equally
effective if given simultaneously with
HN2 or 4 h later. Similar toxicity studies
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TABLE II.-Effect ofphenyl acetic mustard
alone or in combination with equimolar
prednisolone on the cytotoxicity of the
alkylating-agent-resistant Walker 256 as-
cites tumour
% cells excluding
trypan blue at 72 h*
10mg/kg 20mg/kg
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FIG. 1.-Effect ofprednisolone on the
of nitrogen mustard in female Wist
Groups of 10 rats received a sin
injection of HN2, either alone or
bination with an equimolar dose of
solone. Rats were weighed each de
weeks. Numbers on graph indicate
dying on that day. 0 Control (all su
* HN2 (1mg/kg) Only4/10 survival
8 days, A HN2 (1 mg/kg) +PI
mg/kg) simultaneously (all survivec
in male BALB/c mice showed
reduction in HN2 toxicity in th4
of the steroid. PAM is the fi.
product of CHL in both rats
et at., 1976) and man (Newell et
Table I shows that although the
doubled when PAM was used
bination with PRED, the ED(
alkylating-agent-sensitive tumou
increased, producing a similar ti
index (TI). The activity against
with acquired alkylating-agent
was enhanced in a schedule-(
TABLE I.-Toxicity and antitun
of phenyl acetic mustard ah
combination with prednisolone
PAM
treatment LD5o* EDso*
Alone 67 + 10 ND
PRED: 70+ 10 65 + 8
r-. ;;'gr- simultaneously
4hafter 38+8 31+6
; 4 h before 80+12 48+10
toxicity ND =Not determined because this is a lethal dose.
tar rats. Data the + of 3 determinations on
igle s.c. of 5 rats each.
in com- * 100% in untreated tumours.
predni-
ay for 3
animals
Lrvived),
[beyond
.tED (3
an equal
e presence
-oxidation
(McLean
al., 1979). :
LD50 was
I[in corn
go for the
ir was also
herapeutic
a tumour
resistance :
dependent
0*
rour study r\
one or in
TIt
Alone 12-0 2-8 4-3
With PRED: 28-2 4-7 6-0
simultaneously
4 h after 27-5 4-7 5-8
4 h before 21-0 3*5 6 -0
Male Wistar rats bearing the alkylating-agent-
sensitive Walker 256 carcinosarcoma as an i.m.
tumour were used.
* Determined (in mg/kg) using logarithmically
spaced (2-fold) dose levels. Three rats were used per
dose level (Rosenoer et al., 1966). PRED was given
at doses equimolar to the PAM dose, which, because
of their similar mol. wts, were the same in mg/kg.
t TI =therapeutic index: LD5o/ED9o.
F
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FIG. 2.-Effect of PRED on the antitumour
activity of HN2 in the Walker 256 carcino-
sarcoma. Rats carrying the alkylating-
agent sensitive (circles) or resistant
(squares) strains of the Walker tumour
i.m. received a single s.c. injection of HN2
alone (*, *) or in combination with
equimolar PRED (0, Ol). Points are mean
+ s.e. of 3 determinations.
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way (Table II). The greatest tumour
response was when the steroid was given
4 h after the alkylating agent. Similar
schedule dependency has been described
for the CHL/PRED combination (Harrap
et al., 1977). Fig. 2 shows the potentiation
by PRED of the antitumour effect of
HN2. A significant decrease in the growth
rate of the resistant Walker tumour was
achieved, and the response ofthe sensitive
tumour was not compromised. A similar
response was obtained in the sensitive and
resistant lines of the Yoshida sarcoma
(data not shown). Because of the reduced
toxicity of the combination it was pos-
sible to use up to 1 mg/kg of HN2 rather
than 0-8 mg/kg, which is the maximum
tolerated dose of the single agent.
TABLE III.-Toxicity and antitumour study
ofcyclophosphamide alone or in combina-
tion with equimolar prednisolonet
CY
treatment LD5o*
EDgo* Tl*
S R S R
Alone 359 39 -0 280 9 - 2 1-3
PRED: 240 40*0 240 6 -0 1-0
simultaneously
4 h after 220 12-5 118 17-6 1-8
4 h before 270 12-5 228 21-6 1-2
Male Wistar rats bearing either the alkylating-
agent-sensitive (S) or resistant (R) Walker 256
carcinoma as an i.m. tumour were used.
* As in Table I.
t Because the mol. wt of PRED is 1/3 more than
that of CY, the dose of PRED used was 1/3 more in
mg/kg i.e. 30 and 40 mg/kg for CY and PRED
respectively.
Combinations of CY or MEL with
PRED were more toxic than the alkylat-
ing agents alone, and this was also
schedule-dependent. Table III shows that
PRED decreased the LD50 and the ED99
of CY if it was given 4 h before or after
CY. The greatest response in the resistant
tumour was obtained when the steroid
was given 4 h after CY. For both sensitive
and resistant tumours the simultaneous
administration of CY and PRED had the
lowest therapeutic index.
The antitumour activity ofMEL against
a sensitive mouse tumour was not en-
hanced by combination with PRED,
TABLE IV.-Toxicity and antitumour study
on the ADJ/PC6A plasmacytoma in
BALB/c mice
Treatment
MEL
MEL +equimolar
PRED simultaneously
* As in Table I.
LD50*
11*4
8-4
EDso*
0 07
0-1
TI*
162
84
though its toxicity was increased, thus
lowering the TI (Table IV). In the rat,
toxicity was also increased when measured
by body-weight loss and animal deaths
(Fig. 3). MEL alone had an LD50 of
12 mg/kg, whereas the combination of
MEL and PRED simultaneously pro-
duced an LD50 of 5-6 mg/kg. The toxicity
was reduced if the steroid was given 4 h
after MEL. The antitumour activity of
the combination, as measured by Trypan-
blue staining, was significantly increased
against both the Yoshida and Walker
resistant tumour lines, but not against
the sensitive lines as seen in Table V.
Rats bearing resistant lines treated with
MEL alone died at the same time as
FIG. 3. Effect of PRED on the toxicity of
MEL in female Wistar rats. Groups of 10
rat received a single s.c. injection of MEL
either alone or in combination with an
equimolar dose of prednisolone. Rats were
weighed each day for 3 weeks. Numbers on
graph indicate animals dying on that day.
Points are the mean weights up to 10 rats.
* Control, * MEL 8 mg/kg, V MEL 8
mg/kg+PRED 8 mg/kg 4 h later (3 sur-
vived beyond 12 days), V MEL 8 mg/kg+
PRED 8 mg/kg simultaneously (no
survival beyond 8 days), 0 MEL 16 mg/kg
(no survival beyond 6 days).
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TABLE V.-Cytotoxicity of melphalan alone
(2 mg/kg) or in combination with 2 mg/kg
PRED 4 h later to ascites tumours
0% Trypan blue-exeludling
cells at 72 h
MEL +
Tumour Control MEL PRED
Walker sensitive 100 23 + 5 13 + .3
resistant 100 83+ 15 22+10
Yoshida sensitive 100 10+ 5 9 + 4
resistant 100 85+ 10 43+8
Data are the means + s.e. of 3 separate deter-
minations on groups of 5 rats each.
TABLE VI.-Toxi
on the alkylati
256 tumour in
Chlorambucil
Alone
+ Equimolar
PROG 4 1i later
* As in Table I.
controls (7-8 da
bined treatment
longer.
In an approach
influence of the
undertaken pre
PROG. This h
properties from P
can serve as a p:
corticosterone pri
PROG was foun
of PRED in redu
rat (see Table VI
on the ED90 o
tumour so the
alone, at the ma:
32 mg/kg, had ni
tumour, but in c
TABLE VII. T(
study on the
BALB/c mice
Chlorambucil
Alone
+ equimolar PROG
4 h later
+ equimolar PREI)
4 h later
* As in Table I.
there was a 350 inhibition in growth
rate of the tumour. At 64 mg/kg ofCHL
in combination with 64 mg/kg PROG,
inhibition of growth of the resistant
tumour was 66%. This high dose of CHL
could not be given alone, because it
killed all the rats within 1-2 h. It was not
possible to increase the TI of CHL in the
mouse with either PRED or PROG,
as seen in Table VII (also Harrap et al.,
1977).
DISCUSSION
city and antitumour study We have previously shown that PRED ng-agent-sensitive Wvalkcer maleWistar can enhance the TI of CHL in the rat by reducing its systemic toxicity and enhanc-
LD50* ED9o* TI* ing its antitumour activity, especially
41 12 3 4 against alkylating-agent-resistant tumour
95 1.13-5 7 0 cells (Harrap et al., 1977). We have now
extended these studies to other alkylating
agents, and shown that the efficacy of
Lrthe com- HN2 and PAM can be increased similarly.
ys)utvi waf 60-90% The toxicity of both MEL and CY, surviva was 60~~9o0o however, was increased by the simul-
taneous administration of PRED, and no
ttherposibleffeeho ale increase in therapeutic index was obtained steroid effect we have ..
Jiminary studies with against sensitive tumours. The ability of
MEL and CY to decrease the growth rate
RED though the former of alkylating-agent-resistant tumours was 'REcuror cort enhanced by an equimolar dose ofPRED. odcursor (Bor d cortl a Using rats bearing the Yoshida and oduction (Bondy, 1969). Walker tumours, we have shown that id to mimic the effects after treatment with a combination of cilng CHL toxicity in the
i)nThere wslittle effct alkylating agent and steroid there was a . The waseiti eeWlecr greater stimulation of DNA cross-linking fThe sensidoledWaLkr and nuclear-protein phosphorylation than TI was doubled. CHL after treatment with the alkylating agent ximum tolerated dose of alone (Wilkinson et al., 1979). This is o effect on the resistant .' ombinaction withe PrOGin particularly true for resistant tumours "ombination with PROG . and this enhanced nuclear reactivity
provides a possible biochemical basis for )xicity and antitunoar the increased antitumour activity re-
ADJ/PC6A plasma in ported here.
The increased kill of resistant cells is
LD5o* ED9o* TT* similar to that obtained with combina-
38 4 9.5 tions of vincristine and PRED in vitro
24 16 1-5 (Rosner et al., 1975). In man, PRED has
22 8 2 7 proved effective in combination with
alkylating agents for the treatment of
lymphomas (Jelliffe, 1975) and leukaemias
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(Han et al., 1973). In these cases the
steroid alone is cytotoxic. MEL can also
be potentiated in vivo by cobra-venom
cytotoxin P6 (Braganca & Hospattankar,
1978) but again the venom is toxic when
used alone. The antitumour efficacy of
HN2 against a human cell line has been
potentiated by combining it with non-
toxic doses of warfarin (Dolfini et al.,
1980). However, the systemic toxicity of
this combination was not reported. We
have potentiated alkylating-agent activity
against resistant tumour cells by non-
cytotoxic doses ofsteroid, and in the cases
ofHN2, CHL and PAM, without increased
systemic toxicity.
The modulation ofthe systemic toxicity
of alkylating agents by steroids cannot at
present be explained, but is probably
not linked to altered pharmacokinetics,
since PRED does not appear to alter the
pharmacokinetics of CHL (Newell et al.,
1981). The enhanced toxicity of MEL and
CY, but reduced toxicity of HN2, CHL
and PAM may reflect differences in the
modes of action of the individual alkylat-
ing drugs. For example, MEL is actively
transported (Redwood & Colvin, 1980)
but CHL enters by passive diffusion (Hill
et al., 1971). The kinetics of DNA cross-
linking induced by MEL and HN2 are
different (Ross et al., 1978; Brox et al.,
1980): CY has a greater therapeutic
effect on experimental autoimmune disease
than does CHL (Gerber et al., 1977) and
the replacement of HN2 by CHL in the
schedule for Hodgkin's disease resulted in
similar tumour-cell kill but reduced nor-
mal-tissue toxicity (McElwain et al., 1977).
It appears, therefore, that although these
alkylating agents kill dividing rather than
resting cells (Van Putten & Lelieveld,
1971), there are subtle differences in the
spectra of their normal-tissue toxicities
which are enhanced by the steroid.
The ability of PROG to suppress CHL
toxicity in the rat, as does PRED (Harrap
et al., 1977), further supports the theory of
a general corticosteroid response, since
PROG is a precursor for both cortisol
and corticosterone (Bondy, 1969). Coinci-
dentally, in a case of inadvertant CHL
overdose, the patient took prednisone
(80 mg/day) together with the CHL
(56 mg/day) for 5 days and sustained
only moderate pancytopenia, which
quickly recovered (Enck & Bennett,
1977). Possibly the presence of the
steroid contributed towards this low
toxicity.
Diurnal variations in marrow response
(Simpson & Stoney, 1977) or plasma
binding of drug (Hill & Harrap, 1972),
amongst other factors, influence alkylat-
ing-agent toxicity, and these might be
modified by steroids. PRED binds to
plasma proteins and may modify plasma
binding of alkylating agents (El Dareer
et al., 1977). Corticosteroids have an in-
hibitory effect on protein and nucleic-acid
synthesis in lymphoid tissues and inhibit
protein synthesis in muscle, s.c. tissue and
the bone matrix (Kornel, 1973). These
many different properties can be modified
by alkylating agents, e.g. the inhibition of
glucocorticoid response in the rat by CY
(Burroughs & Cidlowski, 1978).
The ability of corticosteroids to cause
selective redistribution of circulating lym-
phocytes (Fauci, 1975; Fauci & Dale,
1974; Cohen, 1972) could possibly modu-
late alkylating-agent toxicity. Indeed such
a mechanism could explain the effects of
methyl prednisolone in combination with
CY, which increased the colony-forming
units in mouse marrow and spleen com-
pared with CY alone (Joyce & Cherve-
chick, 1977). Anabolic effects of PRED,
such as its stimulation of RNA synthesis
(Kornel, 1973) may also modify host
toxicity.
Steroids are already used to treat
lymphoid tumours, where prednisone alone
is effective, and to treat breast carcinoma.
Here again there is experimental evidence
for cytotoxicity of the steroid alone
(Braunschweiger et al., 1978). We would
suggest that our antitumour and host-
toxicity data indicate that the inclusion
of prednisolone in some clinical treatment
schedules using chlorambucil or nitrogen
mustard might be beneficial.
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